Launch of Adjutor Healthcare (NZ) Limited

Adjutor Healthcare announces launch of Adjutor Healthcare New Zealand Limited consulting and sponsorship entity for medicines and medical devices.

This is a very exciting day for me, a Kiwi living and working in Australia. Today, we officially launched our New Zealand entity Adjutor Healthcare (NZ) Limited.

The mission of Adjutor Healthcare (NZ) Limited, and parent company Adjutor Healthcare Pty Ltd is three-fold.

Firstly, we want to help bring international business to the Australia/New Zealand biotech scene and local providers. This includes contract science, contract manufacturing, clinical trials, regulatory and commercialisation.

We know that local experts are well placed to assist international clients with product development and there are many advantages that our region can provide, particularly in the clinical trial space, including: quick study start up, adherence to cGCP, IP security and reasonable cost structures.

Secondly, Adjutor aims to bring more products to Australia and New Zealand patients either through access to clinical trials or as approved products.

Thirdly, we want to help Australian and New Zealand companies capitalise on their new product ideas and IP, move through development efficiently, and launch their products in global markets, in a timely manner.

With Adjutor’s specialised knowledge and an expert network including in- country consultants all around the world, we are extremely well positioned to do this.

We look forward to more local engagement and some interesting projects in future.

Dr Rosalie Cull

More recent articles

  • Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…

  • Australia’s TGA Priority Review Pathway

    Australia’s TGA Priority Review Pathway

    How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…